10-Q: QHSLab Reports Q2 Revenue Growth Amid Rising Losses

QHSLab, Inc. reported increased revenue for Q2 2025 and the first half of 2025, driven by Integrated Service Program and new clinical study revenue, but faced a significantly higher net loss due to increased operating and default interest expenses, raising substantial doubt about its going concern ability.

Summary

• Revenue for the three months ended June 30, 2025, increased by 28% to $605,446 from $473,073 in the prior year period.
• Six-month revenue for 2025 grew by 30% to $1,250,865 compared to $961,660 in the first half of 2024.
• Integrated Service Program (ISP) revenue surged by 64% in Q2 2025 and 48.2% for the six months ended June 30, 2025, reaching $426,130.
• Clinical Study Revenue contributed $89,100 for the first six months of 2025, a new revenue stream.
• Gross profit for the six months ended June 30, 2025, was $828,959, up from $580,603 in the prior year, with gross margin improving to 66.3% from 60.4%.
• Net loss for the three months ended June 30, 2025, significantly widened to $(52,958) from $(2,890) in the same period last year.
• Net loss for the six months ended June 30, 2025, increased to $(132,567) from $(21,415) in the first half of 2024.
• Interest expense more than doubled for the six-month period, reaching $132,054, primarily due to 18% default interest on two convertible notes.
• The company had an accumulated deficit of $4,463,917 as of June 30, 2025.
• Current assets totaled $385,980 and current liabilities were $2,354,356 as of June 30, 2025, indicating a significant working capital deficit.
• Cash and cash equivalents slightly increased to $168,358 at June 30, 2025, from $157,168 at December 31, 2024.
• The company is in default on its $750,000 Promissory Note and two Original Issue Discount Secured Convertible Promissory Notes ($806,000 and $440,000), which were assigned to Catheter Precision, Inc. on May 12, 2025.
• Disclosure controls and procedures were deemed ineffective as of June 30, 2025, due to a lack of adequate personnel with financial reporting experience.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the explicit 'going concern' warning, significant increase in net losses, multiple debt defaults with high default interest rates, and ineffective internal controls. While revenue growth is present, it is overshadowed by severe financial instability and operational challenges. The reliance on lender forbearance for continued operations indicates a precarious financial position.

Positives

• Total revenue increased by 30% for the six months ended June 30, 2025, reaching $1,250,865.
• Integrated Service Program (ISP) revenue showed strong growth, increasing by 48.2% for the six-month period.
• The company recognized $89,100 in new Clinical Study Revenue during the first half of 2025.
• Gross margin improved to 66.3% for the six months ended June 30, 2025, up from 60.4% in the prior year, driven by favorable product mix and synergies.
• Cash and cash equivalents slightly increased to $168,358 at June 30, 2025.

Negatives

• Net loss significantly increased to $(132,567) for the six months ended June 30, 2025, compared to $(21,415) in the prior year period.
• Interest expense more than doubled to $132,054 for the six-month period, primarily due to 18% default interest rates on outstanding convertible notes.
• General and administrative expenses increased by 85% for the six-month period, driven by investor relations, sales processing, cloud hosting, and legal fees.
• Research and development expenses increased by 120% for the six-month period due to software development and consulting expenses.
• Subscription revenue decreased by 43.4% for the six months ended June 30, 2025.
• The company has an accumulated deficit of $4,463,917 and a significant working capital deficit of $1,968,376 as of June 30, 2025.
• The company is in default on multiple convertible notes and a promissory note, totaling over $1.6 million in principal and accrued interest, and relies on forbearance from lenders.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to incurred losses, high leverage, and inconsistent cash from operations.
• The company is in default on its $750,000 Promissory Note and two convertible notes ($806,000 and $440,000), which could lead to lenders exercising their rights, including foreclosure on assets.
• There is no guarantee that the holders of the defaulted notes will continue to forbear from exercising their rights, which could result in immediate payment demands and material adverse effects on the business.
• The interest rate on the defaulted convertible notes has increased to 18% due to default, significantly increasing interest expense.
• The company's disclosure controls and procedures were deemed ineffective due to a lack of adequate personnel, particularly in financial reporting, posing a risk to accurate and timely financial information.
• Future utilization of net operating loss carryforwards ($4,463,917) may be subject to substantial annual limitation due to ownership change limitations, potentially leading to expiration before full utilization.
• The company's ability to obtain future equity or debt financing on commercially reasonable terms is uncertain, which is critical for funding ongoing operations and addressing defaults.
• Additional issuances of equity or convertible debt securities to raise capital will result in dilution to current shareholders and could cause the common stock price to decrease.
• The state of capital markets, influenced by global events like wars and inflation, may adversely impact the company's ability to raise funds.

Future Outlook

The company expects sales and marketing expenses to increase as it seeks to build its customer base and launch additional products. Research and development expenses are also expected to continue increasing as the company invests in expanding operations and developing new products and services. The ability to operate profitably is dependent on achieving increased positive cash flows and continual profitability, and, in the interim, securing future equity or other financings. There is no assurance that current noteholders will continue to forbear from exercising their rights under the defaulted notes.

Management Comments

• We are a medical device technology and software as a service (SaaS) company focused on enabling primary care physicians (PCPs) to increase their revenues by providing them with relevant, value-based tools to evaluate and treat chronic disease as well as provide preventive care through reimbursable procedures.
• We intend to increase our revenues by charging physicians a monthly subscription fee for the use of QHSLab and soliciting additional PCPs to increase their revenues by using our proven revenue generating QHSLab and AllergiEnd line of products.
• We also plan to introduce additional point of care diagnostics and treatments, and digital medicine programs that PCPs can use and prescribe in their practices.
• Our ability to operate profitably is determined by our ability to generate revenues from the licensing of our QHSLab software and the sale of diagnostic related products and treatment protocols and the provision of services through our QHSLab system.
• We will continue to upgrade QHSLab in an effort to increase the number of products sold based upon the services it can provide and for which we are able to charge a fee for its use.
• If we are successful in onboarding a sufficient number of PCPs and maintaining our relationships with these PCPs once they begin to fully utilize our products, sales and marketing expenses could decrease as a percentage of revenues, though we may increase our marketing efforts as funds become available.
• Management has identified corrective actions for the weakness in disclosure controls and will periodically reevaluate our ability to add personnel and implement improved review procedures as they can be supported by the growth in our business.

Industry Context

QHSLab operates in the evolving value-based healthcare and digital therapeutics space, providing SaaS solutions and medical devices to primary care physicians. The company's focus on enabling PCPs to manage chronic conditions and preventive care through reimbursable procedures aligns with broader industry trends towards integrated care and leveraging technology (including AI-enabled digital medicine) to improve patient outcomes and practice revenue. The increasing recognition by regulators and insurance companies of the value of frequent, short encounters for chronic condition management, often supported by digital technologies, suggests a favorable market trend for QHSLab's offerings. However, the company's financial struggles and reliance on debt forbearance indicate challenges in capitalizing on these trends effectively compared to more established or better-funded players in the health tech sector.

Comparison to Industry Standards

• The company's gross margin of 66.3% for the six months ended June 30, 2025, is generally healthy for a SaaS and medical device company, indicating strong unit economics on its products and services. For comparison, many established SaaS companies aim for gross margins above 70-80%, while medical device companies can vary widely but often fall in the 60-75% range.
• The significant increase in net loss and accumulated deficit, coupled with a 'going concern' warning, places QHSLab far below industry standards for financial stability and operational efficiency. Profitable and well-capitalized companies in this sector, such as Teladoc Health (TDOC) or Amwell (AMWL) in digital health, or larger medical device firms like Medtronic (MDT) or Abbott Laboratories (ABT), typically demonstrate consistent profitability or a clear path to it, strong balance sheets, and access to capital markets without default issues.
• The company's reliance on forbearance agreements for its defaulted convertible notes and promissory note, and the 18% default interest rate, are highly unusual and indicative of severe financial distress, contrasting sharply with the financing terms available to financially sound industry peers.
• The reported ineffectiveness of disclosure controls and procedures due to a lack of adequate personnel is a significant corporate governance weakness, which is not typical for publicly traded companies, especially those aiming for growth and investor confidence. Leading companies maintain robust internal control environments to ensure financial reporting integrity.

Corporate Governance

Legal Proceedings

• The company received Notices of Default from Mercer Fund on February 20, 2025, in connection with the $806,000 Note and the $440,000 Note, which were subsequently assigned to Catheter Precision, Inc. on May 12, 2025. Catheter has not yet commenced actions to enforce its rights, and discussions are ongoing to restructure the notes.
• The company is in default on a Promissory Note with MedScience Research Group, Inc., which has provided forbearance but reserves all its rights.

Related Party Transactions

• Amounts due to related parties totaled $13,536 as of June 30, 2025, consisting of cash advances from the principal shareholder that bear no interest and are due on demand.
• A Convertible Promissory Note in the principal amount of $100,000 was issued to a shareholder (Note 1) on May 7, 2021, with terms that may not be indicative of third-party agreements. Its maturity date was extended to December 31, 2025.
• The company's CEO and principal shareholder is a minority shareholder of MedScience Research Group, Inc. and provides services to MedScience for which he is compensated.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future equity raises and a high risk of value impairment due to the 'going concern' warning, increasing losses, and debt defaults. The ineffective internal controls also pose a risk to transparency and investor confidence.
• **Creditors (Noteholders)**: The company is in default on multiple notes, including those assigned to Catheter Precision, Inc. and the Promissory Note with MedScience. While forbearance has been granted, there is no guarantee it will continue, posing a risk of enforcement actions and potential losses for creditors if the company cannot restructure or repay its debts.
• **Employees**: The company's precarious financial position and 'going concern' doubt could impact job security and future growth opportunities.
• **Customers (PCPs)**: Continued operation and development of the QHSLab platform and product lines are dependent on the company's financial stability. Instability could affect service continuity, product availability, and future innovation.
• **Suppliers**: May face payment delays or non-payment if the company's financial situation deteriorates further.

Next Steps

• Engage in discussions with Catheter Precision, Inc. to restructure the defaulted $806,000 Note and $440,000 Note.
• Seek to obtain necessary equity or debt financing to fund ongoing operations and address liquidity issues.
• Implement corrective actions to address deficiencies in disclosure controls and procedures, including adding personnel with financial reporting experience.
• Continue to upgrade the QHSLab platform software to increase product sales and service offerings.
• Introduce additional point of care diagnostics and treatments, and digital medicine programs for PCPs.
• Increase sales and marketing efforts to build the customer base and launch new products.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a 'going concern' warning, a substantial accumulated deficit, and significant net losses that are widening despite revenue growth. Multiple debt instruments are in default, and the company's continued operation relies on the forbearance of lenders, which is not guaranteed. The ineffective internal controls further compound the risk by raising questions about financial reporting reliability. While revenue is growing, the underlying financial structure is highly unstable, making the stock a high-risk investment with significant downside potential. A seasoned investor would likely view these factors as critical red flags, indicating a strong likelihood of further financial deterioration or potential bankruptcy without a significant and uncertain capital infusion or debt restructuring.

Keywords

QHSLab, 10-Q, Quarterly Report, Medical Device Technology, SaaS, Healthcare, Allergy Diagnostics, Immunotherapy, QHSLab Platform, Going Concern, Debt Default, Financial Performance, Revenue Growth, Net Loss, SEC Filing, Corporate Governance, Internal Controls